NCT03807063 - Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant | Biotech Hunter

Timeline

Start Date

January 2, 2020

Primary Completion Date

December 31, 2020

Study Completion Date

December 31, 2021

Conditions

Acute Bilineal LeukemiaMyelodysplastic/Myeloproliferative NeoplasmMyelodysplastic/Myeloproliferative Neoplasm, UnclassifiableMyeloproliferative NeoplasmRecurrent Acute Biphenotypic LeukemiaRecurrent Acute Lymphoblastic LeukemiaRecurrent Acute Myeloid LeukemiaRecurrent Blastic Plasmacytoid Dendritic Cell NeoplasmRecurrent Chronic Lymphocytic LeukemiaRecurrent Chronic Myelogenous Leukemia, BCR-ABL1 PositiveRecurrent Chronic Myelomonocytic LeukemiaRecurrent Myelodysplastic Syndrome

Interventions

BIOLOGICAL

Rivogenlecleucel

Given IV

DRUG

Rimiducid

Given IV

Trial Locations (1)

98109

Fred Hutch/University of Washington Cancer Consortium, Seattle